Vor Biopharma Statistics

Total Valuation

Vor Biopharma has a market cap or net worth of $132.46 million. The enterprise value is $103.20 million.

Market Cap	132.46M
Enterprise Value	103.20M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Vor Biopharma has 124.96 million shares outstanding. The number of shares has increased by 22.58% in one year.

Current Share Class	124.96M
Shares Outstanding	124.96M
Shares Change (YoY)	+22.58%
Shares Change (QoQ)	+78.26%
Owned by Insiders (%)	31.94%
Owned by Institutions (%)	11.49%
Float	39.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.00
P/TBV Ratio	2.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.88, with a Debt / Equity ratio of 0.47.

Current Ratio	3.88
Quick Ratio	3.59
Debt / Equity	0.47
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -125.43% and return on invested capital (ROIC) is -59.97%.

Return on Equity (ROE)	-125.43%
Return on Assets (ROA)	-55.25%
Return on Invested Capital (ROIC)	-59.97%
Return on Capital Employed (ROCE)	-131.93%
Revenue Per Employee	n/a
Profits Per Employee	-$745,887
Employee Count	159
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.83% in the last 52 weeks. The beta is -0.51, so Vor Biopharma's price volatility has been lower than the market average.

Beta (5Y)	-0.51
52-Week Price Change	-7.83%
50-Day Moving Average	0.38
200-Day Moving Average	0.82
Relative Strength Index (RSI)	89.75
Average Volume (20 Days)	33,294,751

Short Selling Information

The latest short interest is 4.19 million, so 3.36% of the outstanding shares have been sold short.

Short Interest	4.19M
Short Previous Month	2.76M
Short % of Shares Out	3.36%
Short % of Float	10.74%
Short Ratio (days to cover)	0.79

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-122.15M
Pretax Income	-118.09M
Net Income	-118.60M
EBITDA	-118.74M
EBIT	-122.15M
Earnings Per Share (EPS)	-$1.43

Full Income Statement

Balance Sheet

The company has $60.04 million in cash and $30.78 million in debt, giving a net cash position of $29.25 million or $0.23 per share.

Cash & Cash Equivalents	60.04M
Total Debt	30.78M
Net Cash	29.25M
Net Cash Per Share	$0.23
Equity (Book Value)	66.07M
Book Value Per Share	0.53
Working Capital	48.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$100.26 million and capital expenditures -$346,000, giving a free cash flow of -$100.61 million.

Operating Cash Flow	-100.26M
Capital Expenditures	-346,000
Free Cash Flow	-100.61M
FCF Per Share	-$0.81

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vor Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.58%
Shareholder Yield	-22.58%
Earnings Yield	-89.54%
FCF Yield	-75.95%

Analyst Forecast

The average price target for Vor Biopharma is $3.90, which is 267.93% higher than the current price. The consensus rating is "Buy".

Price Target	$3.90
Price Target Difference	267.93%
Analyst Consensus	Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1